Oxidized Alpha-1-Antitrypsin as a Potential Biomarker Associated with Onset and Severity of Chronic Obstructive Pulmonary Disease in Adult Population

• Published in: Chronic obstructive pulmonary disease Vol. 15; no. 5; pp. 472 - 478
• Main Authors: Topic, A., Milovanovic, V., Lazic, Z., Ivosevic, A., Radojkovic, D.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 03.09.2018
• Subjects: Chronic obstructive pulmonary disease; oxidized alpha-1-antitrypsin; specific inhibitor activity to elastase; specific inhibitor activity to trypsin; specific inhibitor activity to trypsin; Chronic obstructive pulmonary disease; oxidized alpha-1-antitrypsin; specific inhibitor activity to elastase
• ISSN: 1541-2555; 1541-2563
• DOI: 10.1080/15412555.2018.1541448

Oxidative stress could reduce inhibitor activity of the alpha-1-antitrypsin (A1AT). Oxidative-modified A1AT (oxidized alpha-1-antitrypsin, OxyA1AT) significantly loses ability to protect the lungs from neutrophil elastase. We aimed to investigate OxyA1AT as a potential biomarker associated with onset and severity of chronic obstructive pulmonary disease (COPD) in adult population. The study included 65 patients with COPD (33 smokers and 32 no-smokers) and 46 healthy participants (17 smokers and 29 no-smokers). Determination of OxyA1AT in serum was based on the difference between the inhibitory activities of normal and oxidized A1AT against trypsin and elastase. The level of OxyA1AT was significantly increased in the group of COPD smokers compared to healthy no-smokers (p = 0.030) and COPD no-smokers (p = 0.009). The highest level of OxyA1AT was found in group of smokers with severe and very severe COPD in comparison to the following: no-smokers with the same stage of disease (p = 0.038), smokers with moderate COPD (p = 0.022), and the healthy control group, regardless of the smoking status (control no-smokers p = 0.001 and control smokers p = 0.034). In conclusion, serum level of OxyA1AT would be potentially good biomarker for the assessment of harmful effect of smoking to the onset and severity of COPD. Also, clinical significance of OxyA1AT as prognostic biomarker could be useful in assessing the effectiveness of antioxidant therapy for COPD and emphysema. Suitable and inexpensive laboratory method for determination of OxyA1AT is additional benefit for the introduction of OxyA1AT into routine clinical practice for diagnosis and monitoring of COPD.